

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

Bil.	No. Protokol	Fasa Kajian Klinik	Nama Produk	Nama Pemohon	Pusat Kajian Klinik	Jangkaan Tempoh Masa Kajian Klinik*	Status Permohonan
1	C1B06557	Kajian BE	Nilotinib 200 mg Capsules	Novugen Oncology Sdn. Bhd.	Cliantha Research Limited	Tidak Berkenaan	LULUS
2	C1B06161	Kajian BE	Tranexamic Acid 500 mg Tablet	Hovid Bhd	Cliantha Research Limited	Tidak Berkenaan	LULUS
3	347-25	Kajian BE	Empagliflozin and Metformin Hydrochloride Tablets, 12.5 mg/1000 mg	Novugen Pharma Sdn. Bhd.	AXIS Clinicals Limited	Tidak Berkenaan	LULUS
4	0273-25	Kajian BE	Pantoprazole Enteric-Coated Tablets 40mg	Xepa-Soul Pattinson (Malaysia) Sdn. Bhd.	Lambda Therapeutic Research Ltd.	Tidak Berkenaan	LULUS
5	0274-25	Kajian BE	Pantoprazole Enteric-Coated Tablets 40mg	Xepa-Soul Pattinson (Malaysia) Sdn. Bhd.	Lambda Therapeutic Research Ltd.	Tidak Berkenaan	LULUS
6	TAS6417-302	Fasa III	Zipalertinib 50 mg Tablet Matching Placebo for Zipalertinib 50 mg Tablet Carboplatin, 450mg/45mL (10mg/mL) vial, Concentrate for Solution for Infusion Cisplatin, 50mg/50mL (1mg/mL) vial, Concentrate for Solution for Infusion Pemetrexed, 500mg/20mL (25mg/mL) vial, Concentrate for Solution for Infusion	Questra Clinical Research Sdn. Bhd.	a) Hospital Kuala Lumpur b) Hospital Pulau Pinang c) Sunway Medical Centre d) Hospital Raja Perempuan Zainab II e) Hospital Picaso	12-Feb-2026 hingga 08-Dis-2032	LULUS
7	ARL-25-136	Kajian BE	Empagliflozin and Linagliptin Tablets, 25 mg/5 mg	Novugen Pharma Sdn. Bhd.	Accutest Research Laboratories (I) Pvt. Ltd.	Tidak Berkenaan	LULUS
8	C1B06136	Kajian BE	Aniprazole 10 mg Tablet	Hovid Bhd	Cliantha Research Limited	Tidak Berkenaan	LULUS
9	001/ST/SML-0052/2025	Fasa II	Ursodiol Solution for Injection 625 mg/25 mL (25 mg/mL) Ursochol Tablets 450 mg	Info Kinetics Sdn. Bhd.	a) Hospital Queen Elizabeth b) Hospital Sultanah Nur Zahirah c) Hospital Umum Sarawak d) Hospital Sultanah Aminah	30-Dis-2025 hingga 30-Dis-2026	LULUS
10	MK-1084-007	Fasa III	MK-1084 25 mg Tablets – Spray-dried Intermediate-Based Oral Compressed Tablets (SDI-OCT) MK-1084 50 mg Tablets - Spray-dried Intermediate-Based Oral Compressed Tablets (SDI-OCT) MK-1084 25 mg Tablets - Spray-dried Intermediate-Based Film Coated Tablets (SDI-FCT) MK-1084 50 mg Tablets - Spray-dried Intermediate-Based Film Coated Tablets (SDI-FCT) MK-3475A 165 mg/mL, 2.4mL Sterile Solution for Injection, Pre-Filled Vial MK-3475A 165 mg/mL, 4.8mL Sterile Solution for Injection, Pre-Filled Vial Pemetrexed Disodium (Equivalent to Pemetrexed 500 mg), Lyophilized Powder for IV Infusion, 500mg Cisplatin 1mg/mL, 50mL Concentrate for Solution for Infusion Carboplatin 10 mg/mL, 60 mL Concentrate for Solution for Infusion	Merck Sharp & Dohme (Malaysia) Sdn. Bhd.	a) Hospital Pulau Pinang b) Sarawak General Hospital c) Hospital Sultan Ismail d) University Malaya Medical Centre e) Sunway Medical Centre	01-Dis-2025 hingga 02-Mei-2033	LULUS
11	OP-1250-302	Fasa III	Palazestrant (OP-1250) Film-coated Tablets, 30 mg Palazestrant (OP-1250) Film-coated Tablets, 60 mg Palazestrant (OP-1250) Film-coated Tablets, 90 mg Matching Placebo for Palazestrant (OP-1250) Film-coated Tablets, 30 mg Matching Placebo for Palazestrant (OP-1250) Film-coated Tablets, 60 mg Matching Placebo for Palazestrant (OP-1250) Film-coated Tablets, 90 mg Ribociclib 200 mg Film Coated Tablets Letrozole capsules, 2.5 mg Matching Placebo for Letrozole capsules, 2.5 mg Goserelin 3.6 mg implant in pre-filled syringe	Novotech Clinical Research (M) Sdn. Bhd.	a) Hospital Umum Sarawak (Sarawak General Hospital) b) Institut Kanser Negara c) Beacon Hospital d) Universiti Malaya Medical Centre e) Hospital Pulau Pinang f) Hospital Raja Permaisuri Bainu g) Hospital Kuala Lumpur h) Hospital Wanita dan Kanak-kanak Sabah	12-Jan-2026 hingga 30-Jul-2032	LULUS
12	C1B06552	Kajian BE	Enzalutamide Tablets, 80 mg (T1) Enzalutamide Tablets, 80 mg (T2) Enzalutamide Tablets, 80 mg (T3)	Novugen Oncology Sdn. Bhd.	Cliantha Research Limited	Tidak Berkenaan	LULUS
13	C1B06553	Kajian BE	Enzalutamide Tablets, 80 mg (T1) Enzalutamide Tablets, 80 mg (T2) Enzalutamide Tablets, 80 mg (T3)	Novugen Oncology Sdn. Bhd.	Cliantha Research Limited	Tidak Berkenaan	LULUS
14	0346-25	Kajian BE	Rivaroxaban 10 mg film-coated tablet	Hovid Berhad	Lambda Therapeutic Research Ltd.	Tidak Berkenaan	LULUS
15	CA2400029	Fasa II/III	BMS-986504 200 mg film-coated tablet Matching Placebo for BMS-986504 200 mg film-coated tablet	Syneos Health Malaysia Sdn. Bhd.	a) Universiti Malaya Medical Centre b) Hospital Umum Sarawak	8-Sept-2025 hingga 12-Ogos-2031	LULUS

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

16	1434-0017	Fasa III	BI 764198 film-coated tablets, 20 mg Placebo to BI 764198 film-coated tablets, 20mg	IQVIA RDS Malaysia Sdn. Bhd.	a) Sunway Medical Centre b) University Malaya Medical Centre c) Hospital Tuanku Ja'afar d) Hospital Kuala Lumpur e) Hospital Sultan Idris Shah, Serdang f) Hospital Queen Elizabeth	Jan-2026 hingga Jan-2031	LULUS
17	EFC18244	Fasa II/III	Lunsekimig 300 mg/2 mL (150 mg/mL) solution for injection in pre-filled syringe Matching placebo to Lunsekimig 300 mg/2 mL (150 mg/mL) solution for injection in pre-filled syringe	Sanofi-Aventis (Malaysia) Sdn. Bhd.	a) Universiti Malaya Medical Centre b) Hospital Al Sultan Abdullah Universiti Teknologi MARA c) Hospital Raja Perempuan Zainab II d) Hospital Pulau Pinang e) Hospital Miri f) Hospital Sultan Idris Shah Serdang g) Hospital Sibu	15-Dis-2025 hingga 22-Jan-2030	LULUS
18	0421-24	Kajian BE	Vaxcel Enoxaparin Injection (Ovine) 6000IU (60mg)/0.6mL Prefilled Syringe	Kotra Pharma (M) Sdn. Bhd.	Lambda Therapeutic Research Ltd.	Tidak Berkenaan	LULUS
19	440-24	Kajian BE	Rivaroxaban 20mg Film-Coated Tablets	Xepa-Soul Pattinson (Malaysia) Sdn. Bhd.	AXIS Clinicals Limited	Tidak Berkenaan	LULUS
20	25-VIN-0701	Kajian BE	Sitagliptin and Metformin HCl Extended-Release Tablets, 100 mg/1000 mg	Novugen Pharma Sdn. Bhd.	Veeda Clinical Research Ltd.	Tidak Berkenaan	LULUS
21	25-VIN-0702	Kajian BE	Sitagliptin and Metformin HCl Extended-Release Tablets, 100 mg/1000 mg	Novugen Pharma Sdn. Bhd.	Veeda Clinical Research Ltd.	Tidak Berkenaan	LULUS
22	0136-25	Kajian BE	Telmisartan Tablets 80 mg	Xepa-Soul Pattinson (Malaysia) Sdn. Bhd.	Lambda Therapeutic Research Ltd.	Tidak Berkenaan	LULUS
23	CFUB523A12302B	Fasa III	FUB523 300 mg/2 mL solution for injection in pre-filled syringe with needle safety device (PFS+NSD)	Parexel International (Malaysia) Sdn. Bhd.	a) Hospital Kuala Lumpur b) Hospital Sultan Idris Shah Serdang c) University Malaya Medical Centre d) Hospital Sibu e) Hospital Tengku Ampuan Afzan	01-Apr-2026 hingga 31-Dis-2028	LULUS
24	ITZ101	Kajian BA	Inhibitor Therapeutics Itraconazole Capsule 65 mg Inhibitor Therapeutics Itraconazole Capsule 75 mg Tolsura Capsule 65 mg	Info Kinetics Sdn. Bhd.	Clinical Site: Borneo Kinetics Sdn. Bhd. Bioanalytical Site: Info Kinetics Sdn. Bhd.	01-Apr-2026 hingga 01-Okt-2026	LULUS
25	1438-0012	Fasa III	BI 764532 (Obrixtamig) Powder for Solution for Infusion, 30mg/vial Atezolizumab Concentrate for Solution for Infusion, 1200 mg/vial (60mg/mL) Carboplatin 10mg/ml Concentrate for Solution for Infusion (60ml Vial) Etoposide 20mg/ml Concentrate for Solution for Infusion (5ml vial)	IQVIA RDS Malaysia Sdn. Bhd.	a) Hospital Umum Sarawak b) Institut Kanser Negara c) Hospital Pulau Pinang d) Sunway Medical Centre e) Hospital Wanita dan Kanak-Kanak Sabah	17-Mac-2026 hingga 28-Mei-2029	LULUS
26	80202135SLE3001	Fasa III	Nipocalimab 460 mg (230 mg/mL), 2 mL Prefilled Syringe-Autoinjector Nipocalimab Corresponding Placebo 460 mg (230 mg/mL), 2 mL Prefilled Syringe-Autoinjector	Johnson & Johnson Sdn. Bhd	a) Hospital Umum Sarawak b) University Malaya Medical Centre c) Hospital Sultan Ismail d) Hospital Taiping e) Hospital Putrajaya f) Hospital Sultanah Nur Zahirah g) Hospital Pulau Pinang h) Sunway Medical Centre	27-Mac-2026 hingga 16-Mei-2031	LULUS
27	0272-25	Kajian BE	Celecoxib Capsules 400mg	Xepa-Soul Pattinson (Malaysia) Sdn. Bhd.	Clinical and Bioanalytical site: Lambda Therapeutic Research Ltd., India.	Tidak Berkenaan	LULUS
28	BGB-58067-101	Fasa I	BGB-58067 Tablets, 50mg (24 Tablets/ Bottles) BGB-58067 Tablets, 50mg (31 Tablets/ Bottle) BGB-58067 Tablets, 200mg (24 Tablets/ Bottle) BGB-58067 Tablets, 200mg (31 Tablets/ Bottle) BGB-A317 100mg/10ml Concentrate for Solution for Infusion	BeOne Medicines Sdn. Bhd.	a) Hospital Pulau Pinang b) Hospital Umum Sarawak c) Hospital Kuala Lumpur d) Hospital Raja Perempuan Zainab II e) Universiti of Malaya Medical Centre	01-Apr-2026 hingga 29 Dis-2027	LULUS

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

29	ID-064A303	Fasa III	Cenerimod 4 mg Film-Coated Tablets	Novotech Clinical Research (M) Sdn. Bhd.	a) Sarawak General Hospital b) University Malaya Medical Centre c) Hospital Sibu	01-Apr-2026 hingga 28-Feb-2029	LULUS
30	1434-0027	Fasa II	BI 764198 film-coated tablets, 20mg Placebo to BI 764198 film-coated tablets, 20mg	IQVIA RDS Malaysia Sdn. Bhd.	a) Sunway Medical Centre b) Hospital Sultan Idris Shah, Serdang c) Hospital Selayang	08-Jul-2026 hingga 30-Sept-2028	LULUS
31	BCA101X301	Fasa II/III	Ficerafusp Alfa Lyophilized Powder for Concentrate for Solution for Infusion, 375 mg/vial Pembrolizumab, 25 mg/mL Concentrate for Solution for Infusion, Vial	IQVIA RDS Malaysia Sdn. Bhd.	a) Mount Miriam Cancer Hospital b) Hospital Umum Sarawak c) Hospital Kuala Lumpur d) Hospital Pulau Pinang e) Universiti of Malaya Medical Centre	01-Jun-2026 hingga 06-Ogos-2031	LULUS
32	SNDX-5613-0710	Fasa III	Revumenib (SNDX-5613) 25 mg Tablets Revumenib (SNDX-5613) 110 mg Tablets Revumenib (SNDX-5613) 160 mg Tablets Matching Placebo for Revumenib (SNDX-5613) 25 mg Tablets Matching Placebo for Revumenib (SNDX-5613) 110 mg Tablets Matching Placebo for Revumenib (SNDX-5613) 160 mg Tablets Cytarabine 500 mg/5 ml (100 mg/ml) solution for injection Cytarabine 2 g/20 ml (100 mg/ml) solution for injection Daunorubicin 20 mg powder for solution for infusion or injection Idarubicin 20 mg/20 ml (1 mg/ml) solution for infusion or injection	Parexel International (Malaysia) Sdn. Bhd.	a) Hospital Sultanah Aminah b) Sunway Medical Centre c) Beacon Hospital d) Pantai Hospital Kuala Lumpur	1-Apr-2026 hingga 11-Feb-2031	LULUS
33	TAK-226-3001	Fasa III	Elritercept 100 mg/mL Solution for Injection, 200 mg/vial Retacrit 2 000 IU/0.6 mL Solution for Injection in Pre-filled Syringe	IQVIA RDS Malaysia Sdn. Bhd.	a) Hospital Pulau Pinang b) Hospital Sultanah Aminah c) University Malaya Medical Centre	30-Apr-2026 hingga 30-Apr-2034	LULUS
34	CJDQ443B12105B	Fasa I/II	JDQ443 100 mg Tablet	Parexel International (Malaysia) Sdn. Bhd.	Sarawak General Hospital	01-Jun-2026 hingga 12-Mac-2029	LULUS
35	NW-3509/022/III/2024	Fasa III	Evenamide 15 mg Capsule Matching Placebo to Evenamide Capsule	Victory Pharma Healthcare Sdn. Bhd.	a) Hospital Tuanku Fauziah b) Hospital Sultan Abdul Halim c) Hospital Sentosa Kuching d) Hospital Kuala Lumpur	29-Dis-2025 hingga 31-Mei-2027	LULUS
36	IPPT-CTH-001	Fasa II	Gewelry Ganolux Vegetable Capsule 400mg	Institut Perubatan dan Pergigian Termaju Universiti Sains Malaysia Bertam	Institut Perubatan dan Pergigian Termaju Pusat Perubatan Universiti Sains Malaysia Bertam	01-Okt-2024 hingga 30-Sept-2026	LULUS
37	ARL-26-023	Kajian BE	Eltrombopag Tablets, 75 mg	Novugen Pharma Sdn. Bhd.	Clinical and Bioanalytical site: Accutest Research Laboratories (I) Pvt. Ltd., India	Tidak Berkenaan	LULUS
38	C1B06139	Kajian BE	Empagliflozin Tablet 25mg	Pharmaniaga Manufacturing Berhad	Clinical and Bioanalytical site: Cliantha Research Limited, India	Tidak Berkenaan	LULUS
39	CDAK539A12303	Fasa III	Pelabresib (DAK539) 25 mg film-coated tablets Pelabresib (DAK539) 100 mg film-coated tablets Placebo to Pelabresib (DAK539) 25 mg film-coated tablets Placebo to Pelabresib (DAK539) 100 mg film-coated tablets Ruxolitinib (INC424) 5 mg tablets Ruxolitinib (INC424) 10 mg tablets Ruxolitinib (INC424) 15 mg tablets Ruxolitinib (INC424) 20 mg tablets	Parexel International (Malaysia) Sdn. Bhd.	a) Hospital Umum Sarawak b) Hospital Queen Elizabeth c) Hospital Pulau Pinang d) Hospital Sultanah Aminah e) Hospital Ampang	30-Jun-2026 hingga 30-Jun-2031	LULUS
40	INS1009-312	Fasa III	Treprostinil Palmitil Inhalation Powder 80 µg capsules Treprostinil Palmitil Inhalation Powder 160 µg capsules Treprostinil Palmitil Inhalation Powder 320 µg capsules Treprostinil Palmitil Inhalation Powder 640 µg capsules Treprostinil Palmitil Inhalation Powder placebo capsules	PPD Development (S) Pte. Ltd.	a) Hospital Raja Perempuan Zainab II b) Hospital Umum Sarawak c) Sultan Ahmad Shah Medical Centre at IIUM d) Hospital Sultanah Bahiyah e) Hospital Sultan Idris Shah Serdang	01-Jun-2026 hingga 31-Okt-2031	LULUS
41	R7508-DVT-24120	Fasa III	REGN7508, Powder for solution for infusion, 265mg/vial Aspirin 81mg capsule Placebo to REGN7508, Powder for solution for infusion, 0 mg/vial Placebo to Aspirin capsule	Parexel International (Malaysia) Sdn. Bhd.	a) Hospital Sultan Abdul Halim b) Hospital Tengku Ampuan Afzan c) Hospital Queen Elizabeth II d) Hospital Universiti Sains Malaysia (HUSM) e) University Malaya Medical Centre	05-Dis-2025 hingga 16-Jul-2027	LULUS

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

42	BG-C477-101	Fasa I	BG-C477 100mg Powder for concentrate for solution for infusion Tislelizumab (BGB-A317) 100mg/10ml Concentrate for Solution for Infusion	BeOne Medicines Malaysia Sdn. Bhd.	a) Hospital Umum Sarawak b) Universiti of Malaya Medical Centre (UMMC) c) Institut Kanser Negara d) Hospital Kuala Lumpur e) Sunway Medical Center f) Hospital Wanita dan Kanak-kanak Sabah	01-Jun-2026 hingga 31-Dis-2029	LULUS
43	NN9388-7988	Fasa III	CagriSema 1.0mg/ml + 0.5mg/ml, Solution for Injection CagriSema 2.0 mg/ml + 1.0 mg/ml, Solution for Injection CagriSema 4.0 mg/ml + 2.0 mg/ml, Solution for Injection CagriSema 6.8 mg/ml + 3.4 mg/ml, Solution for Injection CagriSema 9.6mg/ml + 4.8mg/ml, Solution for Injection Placebo cagrilintide B + placebo semaglutide I, Solution for Injection	Novo Nordisk Pharma (M) Sdn. Bhd.	a) Hospital Putrajaya b) University Malaya Medical Center	04-Ogos-2026 hingga 30-Mac 2030	LULUS
44	NN9838-4968	Fasa III	CagriSema 1.0 mg/ml + 0.5 mg/ml, Solution for Injection CagriSema 2.0mg/mL + 1.0mg/mL, Solution for Injection CagriSema 4.0mg/mL + 2.0mg/mL, Solution for Injection CagriSema 6.8mg/mL + 3.4mg/mL, Solution for Injection CagriSema 9.6mg/mL + 4.8mg/mL, Solution for Injection Placebo semaglutide I + semaglutide I 0.5mg/ml, Solution for Injection Placebo semaglutide I + semaglutide I 1.0mg/ml, Solution for Injection Placebo semaglutide I + semaglutide I 2.0mg/ml, Solution for Injection Placebo semaglutide I + semaglutide I 3.4mg/ml, Solution for Injection Placebo semaglutide I + semaglutide I 4.8mg/ml, Solution for Injection Cagrilintide B 2.0mg/ml + placebo semaglutide I, Solution for Injection Cagrilintide B 4.0mg/ml + placebo semaglutide I, Solution for Injection Cagrilintide B 6.8mg/ml + placebo semaglutide I, Solution for Injection Cagrilintide B 9.6mg/ml + placebo semaglutide I, Solution for Injection Placebo cagrilintide B + placebo semaglutide I, Solution for Injection	Novo Nordisk Pharma (M) Sdn. Bhd.	a) Hospital Sibru b) Hospital Tunku Azizah c) University Malaya Medical Center	04-Ogos-2026 hingga 30-Mac 2030	LULUS
45	BX-BE26-AMP-001	Kajian BE	Xaroban Film Coated Tablet 20mg	Y.S.P. Industries (M) Sdn. Bhd.	Clinical Research Ward, Hospital Ampang	Tidak berkenaan	LULUS
46	ARL-26-025	Kajian BE	Dapagliflozin and Metformin HCl Extended-Release Tablets, 10 mg/500 mg	Novugen Pharma Sdn. Bhd.	Clinical and Bioanalytical site: Accutest Research Laboratories (I) Pvt. Ltd., India	Tidak berkenaan	LULUS
47	ARL-26-026	Kajian BE	Dapagliflozin and Metformin HCl Extended-Release Tablets, 10 mg/500 mg	Novugen Pharma Sdn. Bhd.	Clinical and Bioanalytical site: Accutest Research Laboratories (I) Pvt. Ltd., India	Tidak berkenaan	LULUS
48	C1B06658	Kajian BE	Vonoprazan Film Coated Tablets 20mg	Hovid Berhad	Clinical and Bioanalytical site: Clantha Research Limited, India	Tidak berkenaan	LULUS
49	CLOU064J12303B	Fasa III	LOU064 (Remibrutinib) 10mg film-coated tablet LOU064 (Remibrutinib) 25mg film-coated tablet Matching placebo to LOU064 (Remibrutinib) 10mg film-coated tablet Matching placebo to LOU064 (Remibrutinib) 25mg film-coated tablet	Parexel International (Malaysia) Sdn. Bhd.	a) Sarawak General Hospital b) Hospital Raja Permaisuri Bainun c) Hospital Selayang d) Hospital Queen Elizabeth	01-Sept-2026 hingga 31-Okt-2032	LULUS
50	78934804CRD3001	Fasa III	JNJ-78934804 (Guselkumab 160 mg/Golimumab 80 mg), 1.6 mL Pre-Filled Syringe Autoinjector Guselkumab 200 mg, 2.0 mL Pre-filled Syringe Autoinjector	Johnson & Johnson Sdn. Bhd.	a) University Malaya Medical Centre b) Sultan Idris Shah Hospital c) Hospital Ampang d) Hospital Queen Elizabeth e) Hospital Sultanah Nur Zahirah	31-Ogos-2026 hingga 08-Jan-2031	LULUS
51	79635322MMY2002	Fasa II	Ramantamig (JNJ-79635322) 5 mg (5 mg/mL), 1 mL solution in vial Ramantamig (JNJ-79635322) 100 mg (50 mg/mL), 2 mL solution in pre-filled syringe Tocilizumab 200 mg (20 mg/mL), 10 mL solution in vial Tocilizumab 400 mg (20 mg/mL), 20 mL solution in vial	Johnson & Johnson Sdn. Bhd.	a) Hospital Queen Elizabeth b) Hospital Sultanah Aminah c) Hospital Ampang d) Hospital Umum Sarawak e) Hospital Pulau Pinang	06-Jul-2026 hingga 21-Feb-2031	LULUS

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

52	D7260C00022	Fasa III	Tablet Elecglipton (AZD5004) 5mg Tablet Elecglipton (AZD5004) 15mg Tablet Elecglipton (AZD5004) 20mg Tablet Elecglipton (AZD5004) 45mg Placebo for Tablet Elecglipton (AZD5004)	AstraZeneca Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Seri Manjung c) Hospital Miri d) Hospital Umum Sarawak e) Hospital Sultanah Bahiyah f) Klinik Kesihatan Seremban 2 g) Hospital Sungai Buloh h) Hospital Putrajaya	01-Ogos-2026 hingga 12-Jun-2028	LULUS
53	NN9490-8266	Fasa III	NNC0487-0111 B 0.80 mg/mL solution for injection NNC0487-0111 B 1.67 mg/mL solution for injection NNC0487-0111 B 3.35 mg/mL solution for injection NNC0487-0111 B 6.7 mg/mL solution for injection NNC0487-0111 B 13.4 mg/mL solution for injection NNC0487-0111 B 26.8 mg/mL solution for injection Placebo G solution for injection	Novo Nordisk Pharma (M) Sdn. Bhd.	a) Hospital Sultanah Bahiyah b) Hospital Sultan Idris Shah Serdang c) Hospital Tengku Ampuan Afzan d) Universiti Malaya Medical Centre e) Universiti Teknologi MARA, Sungai Buloh Campus f) Hospital Universiti Sains Malaysia g) Institut Jantung Negara h) Hospital Canselor Tuanku Muhriz UKM i) Hospital Kuala Lumpur j) Hospital Umum Sarawak k) Hospital Miri l) Cardiac Vascular Sentral Kuala Lumpur m) Hospital Taiping n) Hospital Sultanah Aminah o) Hospital Tuanku Fauziah p) Hospital Pakar Sultanah Fatimah Muar	11-Ogos-2026 hingga 11-Ogos-2029	LULUS
54	ID-06B301	Fasa III	Cenerimod 4 mg Film-Coated Tablets Matching Placebo for Cenerimod 4 mg Film-Coated Tablets	Novotech Clinical Research (M) Sdn. Bhd.	a) Hospital Sultan Idris Shah Serdang b) Hospital Sibul c) Hospital Canselor Tuanku Muhriz UKM d) Universiti Malaya Medical Centre e) Hospital Sultan Abdul Aziz Shah UPM f) Hospital Raja Permaisuri Bainun g) Hospital Umum Sarawak h) Hospital Sungai Buloh i) Hospital Kuala Lumpur	23-Jul-2026 hingga 30-Jun-2030	LULUS
55	42847922MDD3011	Fasa III	Seltorexant (JNJ-42847922) 20 mg, film-coated tablet Matching Placebo for Cenerimod 4 mg Film-Coated Tablets	Johnson & Johnson Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Tuanku Jaafar c) Hospital Raja Permaisuri Bainun d) Hospital Permai e) Hospital Sibul	-	LULUS
56	BGB-43395-302	Fasa III	BGB-43395 Tablets 100mg, F-03 BGB-43395 Tablets 200mg, F-03 BGB-43395 Tablets 400mg, F-03 Letrozole 2.5 mg Tablets Abemaciclib Film Coated Tablets, 50mg Abemaciclib Film Coated Tablets, 100mg Abemaciclib Film Coated Tablets, 150mg Ribociclib Film Coated Tablets, 200mg Palbociclib Film Coated Tablets, 75mg Palbociclib Film Coated Tablets, 100mg Palbociclib Film Coated Tablets, 125mg	BeOne Medicines Malaysia Sdn. Bhd.	a) Hospital Umum Sarawak b) Hospital Kuala Lumpur c) Hospital Pulau Pinang d) Hospital Wanita Kanak Kanak Sabah e) Institut Kanser Negara f) Hospital Picaso g) University Malaya Medical Centre	30-Jul-2026 hingga 05-Dis-2037	LULUS
57	031-26	Kajian BE	Atorvastatin 80 mg Film-Coated Tablet	Hovid Berhad	ZenRise Clinical Research Private Limited, India	Tidak berkenaan	LULUS
58	TEMCI-1	Fasa II	AVS-T3-01 Mixed tocotrienols 120mg softgel AVS-T3-02 Placebo for Mixed tocotrienols 120mg softgel	Universiti Sains Malaysia	a) Hospital Seberang Jaya b) Hospital Taiping c) Kek Lok Si Charitable Hospital	01-Dis-2025 hingga 01-Dis-2027	LULUS
59	BE. 1217/EQL/2026	Kajian BE	Rispedron Film Coated Tablet 1mg	Y.S.P. Industries (M) Sdn. Bhd.	PT Equilib International, Indonesia	Tidak berkenaan	LULUS

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

60	BV100-012	Fasa II	BV100 Vial 1 (300 mg Rifabutin in 0.9mL), concentrate for solution for Infusion BV100 Vial 2 (28 mg Acetic Acid/ 0.7 mL WFI) concentrate for solution for infusion Polymyxin B powder for solution for infusion, 500,000 Units/vial Ceftazidime/avibactam (Zaficefta®) Powder for solution for infusion 2g/0.5g Cefiderocol (Fetroja®) For injection 1 g Aztreonam For injection, 2 g	Victory Pharma Healthcare Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Umum Sarawak c) Hospital Pulau Pinang d) Hospital Raja Permaisuri Bainun	15-Jun-2026 hingga 15-Feb-2029	LULUS
61	78934804UCO3001	Fasa III	JNJ-78934804 (guselkumab 160 mg/golimumab 80 mg), 1.6 mL Pre-Filled Syringe Autoinjector Guselkumab 200 mg, 2 mL Pre-filled Syringe Autoinjector	Johnson & Johnson Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Sultan Idris Shah, Serdang c) Hospital Ampang d) Hospital Kuala Lumpur e) Hospital Sultanah Nur Zahirah	29-Mei-2026 hingga 30-Okt-2030	LULUS
62	1305-0052	Fasa III	Nerandomilast (BI 1015550) 9mg Film-coated Tablets Nerandomilast (BI 1015550) 18mg Film-coated Tablets Matching Placebo to Nerandomilast (BI 1015550) Film-Coated Tablets 9mg Matching Placebo to Nerandomilast (BI 1015550) Film-Coated Tablets 18mg	IQVIA RDS Malaysia Sdn. Bhd.	a) Universiti Malaya Medical Centre b) Hospital Selayang c) Hospital Umum Sarawak	28-Ogos-2026 hingga 31-Jul-2030	LULUS
63	D7261C00006	Fasa III	Tablet Elecglipton (AZD5004) 5mg Tablet Elecglipton (AZD5004) 15mg Tablet Elecglipton (AZD5004) 20mg Tablet Elecglipton (AZD5004) 45mg Placebo for Tablet Elecglipton (AZD5004)	AstraZeneca Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Miri c) Hospital Tuanku Ja'afar d) Hospital Putrajaya e) Hospital Selayang	01-Jul-2026 hingga 01-Ogos-2029	LULUS
64	D7265C00001	Fasa III	Tablet Elecglipton (AZD5004) 5mg Tablet Elecglipton (AZD5004) 15mg Tablet Elecglipton (AZD5004) 20mg Tablet Elecglipton (AZD5004) 45mg Placebo for Tablet Elecglipton (AZD5004) Dapagliflozin 10mg Tablet	AstraZeneca Sdn. Bhd.	a) Hospital Raja Permaisuri Bainun b) University Malaya Medical Centre b) Hospital Miri c) Hospital Seri Manjung d) Prince Court Medical Center e) Hospital Tengku Ampuan Rahimah	06-Jul-2026 hingga 30-Sept-2028	LULUS
65	J2A-MC-GZPW	Fasa III	Orforglipron 0.8 mg Orforglipron 2.5 mg Orforglipron 5.5 mg Orforglipron 9.0 mg Orforglipron 14.5 mg Orforglipron 17.2 mg Matching Placebo LY3502970 (Orforglipron) 0.8mg Tablet Matching Placebo LY3502970 (Orforglipron) 2.5 mg Tablet Matching Placebo LY3502970 (Orforglipron) 5.5mg Tablet Matching Placebo LY3502970 (Orforglipron) 9.0mg Tablet Matching Placebo LY3502970 (Orforglipron) 14.5mg Tablet Matching Placebo LY3502970 (Orforglipron) 17.2 mg Tablet	IQVIA RDS Malaysia Sdn. Bhd.	a) Hospital Tunku Jaafar b) Hospital Raja Permaisuri Bainun c) Hospital Raja Perempuan Zainab II d) University Malaya Medical Centre	10-Jul-2026 hingga 16-Jan-2031	LULUS
66	BX-BE26-AMP-002	Kajian BE	Xaroban Film Coated Tablet 10mg	Y.S.P. Industries (M) Sdn. Bhd.	Clinical Research Ward, Hospital Ampang	03-Ogos-2026 hingga 15-Sept-2026	LULUS
67	GB-0895-302	Fasa III	GB-0895 150 mg/mL (300 mg/vial) Solution for Injection Sodium Chloride, USP, 0.9%; 10 ml/per vial, Solution for Injection	Victory Pharma Healthcare Sdn. Bhd.	a) Hospital Queen Elizabeth b) Hospital Miri c) Hospital Sungai Buloh d) Hospital Raja Permaisuri Bainun e) Hospital Tengku Ampuan Afzan	16-Okt-2026 hingga 31-Dis-2030	LULUS
68	0179-26	Kajian BE	Apixaban Tablet 5mg	Pharmaniaga Manufacturing Berhad	Lambda Therapeutic Research Ltd., India	Tidak berkenaan	LULUS
69	D7261C00004	Fasa III	Tablet Elecglipton (AZD5004) 5mg Tablet Elecglipton (AZD5004) 15mg Tablet Elecglipton (AZD5004) 20mg Tablet Elecglipton (AZD5004) 45mg Placebo for Tablet Elecglipton (AZD5004) Dapagliflozin 10mg Tablet	AstraZeneca Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Miri c) Hospital Tuanku Ja'afar d) Hospital Putrajaya e) Hospital Selayang	06-Jul-2026 hingga 30-Dis-2028	LULUS
70	1438-2025	Kajian BE	Metformin 750 mg extended-release tablet	Hovid Bhd	ACDIMA Center for Bioequivalence and Pharmaceutical Studies, Jordan	Tidak berkenaan	LULUS

STATUS KELULUSAN PERMOHONAN CTIL & CTX 2026 (Jan-Julai)

71	1440-2025	Kajian BE	Metformin 1000 mg extended-release tablet	Hovid Bhd	ACDIMA Center for Bioequivalence and Pharmaceutical Studies, Jordan	Tidak berkenaan	LULUS
72	D7266C00001	Fasa III	Tablet Elecglipton (AZD5004) 5mg Tablet Elecglipton (AZD5004) 15mg Tablet Elecglipton (AZD5004) 20mg Tablet Elecglipton (AZD5004) 45mg Tablet Placebo for Elecglipton (AZD5004) Tablet Dapagliflozin 10mg	AstraZeneca Sdn. Bhd.	a) Hospital Sultanah Bahiyah b) Institut Jantung Negara c) Hospital Miri d) Hospital Umum Sarawak e) University Malaya Medical Centre f) Hospital Sultanah Nur Zahirah g) UiTM h) Hospital Tengku Ampuan Afzan i) Hospital Kuala Lumpur j) Hospital Canselor Tuanku Muhriz	03-Ogos-2026 hingga 31-Dis-2029	LULUS
73	CDX0159-17	Fasa III	Barzolvolimab (CDX-0159) 150 mg/ml solution for injection in 1ml pre-filled syringe Epinephrine injection, USP auto-injector, 0.3mg pre-filled autoinjectors	PPD Development (S) Pte. Ltd	a) Hospital Raja Permaisuri Bainun b) Hospital Kuala Lumpur c) Hospital Pulau Pinang d) Hospital Sultan Ismail e) Hospital Umum Sarawak	01-Julai-2026 hingga 01-Julai-2028	LULUS
74	D7261C00003	Fasa III	Tablet Elecglipton (AZD5004) 5mg Tablet Elecglipton (AZD5004) 15mg Tablet Elecglipton (AZD5004) 20mg Tablet Elecglipton (AZD5004) 45mg Placebo for Tablet Elecglipton (AZD5004) Dapagliflozin 10mg Tablet Placebo for Tablet Dapagliflozin 10mg	AstraZeneca Sdn. Bhd.	a) University Malaya Medical Centre b) Hospital Seri Manjung c) Hospital Miri d) Klinik Kesihatan Greentown e) Hospital Tuanku Fauziah f) Klinik Kesihatan Seremban 2 g) Klinik Kesihatan Simpang Kuala	06-Julai-2026 hingga 27-Julai-2028	LULUS
75	RZ-629-EN-01	Fasa I	RZ-629 tablet 2 mg RZ-629 tablet 5 mg Placebo to match RZ-629 tablet 2mg Placebo to match RZ-629 tablet 5mg	CSI Clinical Research Sdn. Bhd	a) Sarawak General Hospital b) Hospital Ampang	01-Jan-2026 hingga 01-Jan-2027	LULUS
76	NN7769-7602	Fasa III	Denecimig 5.0 mg/mL solution for injection Denecimig 11.3 mg/mL solution for injection Denecimig 25.0 mg/mL solution for injection Denecimig 57.5 mg/mL solution for injection	Novo Nordisk Pharma (M) Sdn. Bhd.	a) Hospital Ampang b) Hospital Queen Elizabeth c) Hospital Umum Sarawak	18-Sept-2026 hingga 15-Jun-2029	LULUS
77	SPR207796	Fasa II	Nemolizumab 30 mg lyophilized powder for solution for injection Placebo lyophilized powder for solution for injection	PPD Development (S) Pte. Ltd.	a) Hospital Umum Sarawak b) University Malaya Medical Centre	30-Okt-2026 hingga 31-Ogos-2031	LULUS
78	C1B07072	Kajian BE	Escitalopram Film-Coated Tablet 20mg	Hovid Berhad	Cliantha Research Limited, India	Tidak berkenaan	LULUS
*Data adalah diperolehi daripada laman sesawang National Medical Research Register (NMRR). Sila layari https://nmrr.gov.my/research-directory untuk maklumat terkini dan lanjut.							